5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole,
AN 2690,
AN-2690,
AN2690,
Kerydin,
tavaborole,
Tavaborole,
174671-46-6,
AN-2690,
5-FLUOROBENZO[C][1,2]OXABOROL-1(3H)-OL,
Kerydin,
AN2690,
AN 2690,
2,1-Benzoxaborole, 5-fluoro-1,3-dihydro-1-hydroxy-,
UNII-K124A4EUQ3,
5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol,
5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole,
K124A4EUQ3,
CHEBI:77942,
5-fluoro-2,1-benzoxaborol-1(3H)-ol,
C7H6BFO2,
5-Fluoro-1-hydroxyl-1,3-dihydrobenzo[c][1,2]oxaborole,
5-Fluoro-3H-benzo[c][1,2)oxaborol-1-ol,
5-fluoro-3H-benzo[c][1,2]oxaborol-1-ol,
Tavaborole [USAN:INN],
Kerydin (TN),
Tavaborole (USAN),
SCH-900340,
tavaborole-an-2690,
AN-2690(Tavaborole),
Tavaborole (AN-2690),
SCHEMBL500016,
CHEMBL443052,
CTK8H2675,
HSDB 8342,
KS-00000SPV,
DTXSID00169888,
LFQDNHWZDQTITF-UHFFFAOYSA-N,
BCP08730,
EX-A1086,
3338AH,
BDBM50370987,
MFCD10699483,
AKOS006303927,
ZINC169990691,
CS-1058,
DB09041,
DS-8392,
MB08883,
NCGC00264110-01,
AK163946,
HY-10980,
SY038332,
5-fluoro-1-hydroxy-3H-2,1-benzoxaborole,
FT-0697827,
ST24044751,
X3699,
MFCD10699483 (95%),
A14999,
D10169,
W-5454,
1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole,
Z1739256284,
Tavaborole [USAN],
D05VGL,
AIDS471673,
ACN-037992,
CID11499245,
AN-2690),
A3177,
Topical antifungal (onychomycosis), Merck & Co,
Trichophyton-targeting antifungal (onychomycosis), Merck & Co,
Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Merck & Co/Anacor,
Trichophyton-targeting antifungal (onychomycosis), Anacor Pharmaceuticals/Schering-Plough,
Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Anacor Pharmaceuticals/Schering-Plough,